Israeli pharmaceutical company Teva receives Chinese approval for new Huntington's treatment
The approval to provide the tablets in China that treat the deadly neurological disease is the second in the world after the United States.
A major Israel-American pharmaceutical company can now sell its medication for treating Huntington’s disease in China.
Teva Pharmaceuticals received approval from China’s National Medical Products Administration for its Austedo tablets that treat the deadly neurological disease, the company said in a press release today. China is only the second country to approve the use and sale of the Huntington’s medication, Teva Pharmaceuticals said. The other country is the United States.
“We look forward to bringing more of the essential medicines in our portfolio to patients in China, and to fuel organic growth and expand our presence in this important market,” Gianfranco Nazzi, Teva’s executive vice president for international markets, said in the release.
Teva is listed on both the New York and Tel Aviv stock exchanges, and has offices in both Israel and the United States.
